Trial Profile

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reloxaliase (Primary)
Indications Hyperoxaluria; Primary hyperoxaluria
Focus Therapeutic Use
Acronyms Study 206
Sponsors Allena Pharmaceuticals

Most Recent Events

08 Jan 2021 Results published in the Nephrology Dialysis Transplantation
18 May 2020 Results (n=14) from this study, were presented at the 115th Annual Meeting of the American Urological Association.
13 May 2020 According to an Allena Pharmaceuticals media release, data from this trial will be presented at the American Urological Association (AUA) Virtual Education Experience, which is being held in place of the cancelled AUA 2020 Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com